(Total Views: 189)
Posted On: 09/14/2017 10:27:47 AM
Post# of 72447
Sounds to me like one or more of the BP's are interested In Kevitrin. Interested enough to ask IPIX to conduct this specific quick trial. Reading between the lines I would think at least one BP will be ready to pony up if the results are good. Go IPIX!!!
From the PR:
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
Initial preliminary study results are anticipated in 4th quarter 2017.
From the PR:
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
Initial preliminary study results are anticipated in 4th quarter 2017.
(5)
(0)
